Agios to Present New Clinical Data from its IDH Programs at ASCO

World News: . []

– –

CAMBRIDGE, Mass., May 16, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that new data from its isocitrate dehydrogenase (IDH) programs will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2018 in Chicago.

In total, five abstracts led by Agios describing new data from the company's IDH programs have been accepted for presentation at ASCO, as well as one abstract led by Celgene Corporation. IDHIFA (enasidenib) is being commercialized in collaboration with Celgene.

The accepted abstracts are listed below and are available online on the ASCO conference website: . 

More news and information about Agios Pharmaceuticals, Inc.

Published By:

Globe Newswire: 22:02 GMT Wednesday 16th May 2018

Published: .

Search for other references to "agios" on SPi News

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us

Advertising on SPi News: Information For Advertisers